<DOC>
	<DOCNO>NCT02739633</DOCNO>
	<brief_summary>Phase II Study Weekly Genexol®-PM Plus Gemcitabine Subjects With Recurrent Metastatic Adenocarcinoma Pancreas .</brief_summary>
	<brief_title>Study Weekly Genexol®-PM Plus Gemcitabine Subjects With Recurrent Metastatic Adenocarcinoma Pancreas</brief_title>
	<detailed_description>The aim phase II study ass efficacy safety combination treatment Genexol®-PM plus gemcitabine patient recurrent metastatic adenocarcinoma pancreas .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Patient definitive histologically cytologically confirm recurrent metastatic adenocarcinoma pancreas . The definitive diagnosis recurrent metastatic pancreatic adenocarcinoma make integrate histopathological data within context clinical radiographic data . Patients islet cell neoplasms exclude . 2 . Initial diagnosis recurrent metastatic disease must occur ≤6 week prior randomization study . 3 . Patient one lesion measurable CT scan MRI ( patient allergic CT contrast medium ) . 4 . Male nonpregnant nonlactating female , ≥ 20 year age . 5 . Patient must meet follow blood count Baseline ( obtain ≤14 day prior randomization ) : Absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/L Platelet count ≥ 100,000/mm3 ( 100 × 10^9/L ) Hemoglobin ( Hgb ) ≥ 9 g/dL . 6 . Patient follow blood chemistry level Baseline ( obtain ≤14 day prior randomization ) : AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 × upper limit normal range ( ULN ) , unless liver metastases clearly present , ≤ 5 × ULN allow . Total bilirubin ≤ULN 7 . Patient Karnofsky performance status ( KPS ) ≥ 70 . Two observer require assess KPS . If discrepant , one low assessment consider true . 8 . Patient voluntarily agree participate study , sign Informed Consent Form ( ICF ) prior participation studyrelated activity . 1 . History malignancy last 5 year . Patients prior history situ cancer basal squamous cell skin cancer eligible . Patients malignancy eligible cured surgery alone surgery plus radiotherapy continuously diseasefree least 5 year . 2 . Patients uncontrolled bacterial , viral , fungal infection 3 . Patient known historical active infection HIV , hepatitis B , hepatitis C. 4 . Patients history allergy hypersensitivity Paclitaxel , Gemcitabine , Cremophor EL . 5 . Patients high cardiovascular risk , include recent coronary stenting myocardial infarction past 6 month . 6 . History Peripheral Artery Disease ( e.g , . claudication , Leo Buerger 's disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Recurrent metastatic adenocarcinoma pancreas</keyword>
	<keyword>Genexol-PM</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>